A Phase I, Open-Label, Parallel-Group, Multiple-Dose Study to Determine the Pharmacokinetics of Favipiravir in Volunteers With Hepatic Impairment and in Healthy Control Volunteers
Phase of Trial: Phase I
Latest Information Update: 27 Oct 2015
At a glance
- Drugs Favipiravir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Sponsors FUJIFILM Corporation; MDVI; Toyama Chemical
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2012 Planned end date changed from 1 Oct 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 08 Feb 2012 Company added in association field as reported by ClinicalTrials.gov.